Regression of CD8+ pseudolymphoma after HIV antiviral triple therapy.
To our knowledge, we report the first case of improvement of HIV-associated cutaneous CD8(+) pseudolymphoma with highly active antiretroviral therapy. This favors the hypothesis of a reactive cutaneous infiltration by HIV-specific cytotoxic T cells in this disease.
Schartz
Noël Emile Célestin
NE
Department of Dermatology, Hôpital Saint-Louis AP-HP, Paris, France.
De La Blanchardiére
Arnaud
A
Alaoui
Siham
S
Morel
Patrice
P
Sigaux
François
F
Vignon-Pennamen
Marie-Dominique
MD
Flageul
Béatrice
B
Lebbé
Céleste
C
D023241:Antiretroviral Therapy, Highly Active; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism*; D017809:Fatal Outcome; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000150:complications / Q000188:drug therapy*; D016410:Lymphoma, T-Cell, Cutaneous / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D019310:Pseudolymphoma / Q000150:complications / Q000188:drug therapy*; D012074:Remission Induction; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy*; D013226:Status Epilepticus / Q000150:complications